WYETH/INTERNEURON REDUX POSTS $116.7 MIL. IN SALES THROUGH NOVEMBER; GLAXO's ZANTAC NOSES OUT ASTRA MERCK's PRILOSEC TO RETAIN TOP-SELLING SPOT IN U.S. FOR 1996
Executive Summary
Wyeth-Ayerst/Interneuron's anti-obesity agent Redux generated $116.7 mil. in U.S. sales from its May launch through November, according to IMS America. Through December, 2.4 mil. prescriptions were written for Redux.